# BTCS Inc.: financial statements, quarterly BTCS · Nasdaq · CIK 1436229 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/btcs.md) · [Financials](/companies/btcs/financials.md) · [Filings](/companies/btcs/filings.md) · [Insiders](/companies/btcs/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/btcs/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.3](/filings/0001493152-24-045124.md) | [0.3 d](/filings/0001493152-25-010973.md) | [0.5](/filings/0001641172-25-010401.md) | [0.6](/filings/0001641172-25-023517.md) | [0.7](/filings/0001493152-25-022359.md) | [2.3 d](/filings/0001493152-26-012916.md) | [1.7](/filings/0001493152-26-023129.md) | [2.8](/filings/0001493152-26-039249.md) | [4.9](/filings/0001493152-25-022359.md) | [7.1 d](/filings/0001493152-26-012916.md) | [2.1](/filings/0001493152-26-023129.md) | [2.4](/filings/0001493152-26-039249.md) | | Cost of revenue | $m | [0.1](/filings/0001493152-24-045124.md) | [0.1 d](/filings/0001493152-25-010973.md) | [0.2](/filings/0001641172-25-010401.md) | [0.2](/filings/0001641172-25-023517.md) | [0.5](/filings/0001493152-25-022359.md) | [2.3 d](/filings/0001493152-26-012916.md) | [1.6](/filings/0001493152-26-023129.md) | [2.9](/filings/0001493152-26-039249.md) | [3.9](/filings/0001493152-25-022359.md) | [6.2 d](/filings/0001493152-26-012916.md) | [1.1](/filings/0001493152-26-023129.md) | [1.0](/filings/0001493152-26-039249.md) | | Gross profit | $m | [0.2](/filings/0001493152-24-045124.md) | [0.2 d](/filings/0001493152-25-010973.md) | [0.3](/filings/0001641172-25-010401.md) | [0.4](/filings/0001641172-25-023517.md) | [0.2](/filings/0001493152-25-022359.md) | [0.1 d](/filings/0001493152-26-012916.md) | [0.1](/filings/0001493152-26-023129.md) | [(0.1)](/filings/0001493152-26-039249.md) | [1.1](/filings/0001493152-25-022359.md) | [0.9 d](/filings/0001493152-26-012916.md) | [1.0](/filings/0001493152-26-023129.md) | [1.5](/filings/0001493152-26-039249.md) | | Research and development | $m | [0.1](/filings/0001493152-24-045124.md) | [0.2 d](/filings/0001493152-25-010973.md) | [0.1](/filings/0001641172-25-010401.md) | [0.2](/filings/0001641172-25-023517.md) | [0.2](/filings/0001493152-25-022359.md) | [0.2 d](/filings/0001493152-26-012916.md) | [0.2](/filings/0001493152-26-023129.md) | [0.2](/filings/0001493152-26-039249.md) | [0.1](/filings/0001493152-25-022359.md) | [0.1 d](/filings/0001493152-26-012916.md) | [0.1](/filings/0001493152-26-023129.md) | [0.1](/filings/0001493152-26-039249.md) | | Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001641172-25-023517.md) | [0.7](/filings/0001493152-25-022359.md) | [0.8 d](/filings/0001493152-26-012916.md) | [0.5](/filings/0001493152-26-023129.md) | [0.4](/filings/0001493152-26-039249.md) | | Net income | $m | [(3.3)](/filings/0001493152-24-045124.md) | [7.3 d](/filings/0001493152-25-010973.md) | [12.3](/filings/0001641172-25-010401.md) | [(6.7)](/filings/0001641172-25-023517.md) | [(9.0)](/filings/0001493152-25-022359.md) | [2.2 d](/filings/0001493152-26-012916.md) | [(17.3)](/filings/0001493152-26-023129.md) | [3.9](/filings/0001493152-26-039249.md) | [65.6](/filings/0001493152-25-022359.md) | [(85.6) d](/filings/0001493152-26-012916.md) | [(69.2)](/filings/0001493152-26-023129.md) | [(34.9)](/filings/0001493152-26-039249.md) | | Diluted EPS | $ per share | [(0.23)](/filings/0001493152-24-045124.md) | not reported | [0.63](/filings/0001641172-25-010401.md) | [(0.43)](/filings/0001641172-25-023517.md) | [(0.56)](/filings/0001493152-25-022359.md) | not reported | [(0.86)](/filings/0001493152-26-023129.md) | [0.14](/filings/0001493152-26-039249.md) | [1.30](/filings/0001493152-25-022359.md) | not reported | [(1.43)](/filings/0001493152-26-023129.md) | [(0.70)](/filings/0001493152-26-039249.md) | | Basic EPS | $ per share | [(0.23)](/filings/0001493152-24-045124.md) | not reported | [0.78](/filings/0001641172-25-010401.md) | [(0.43)](/filings/0001641172-25-023517.md) | [(0.56)](/filings/0001493152-25-022359.md) | not reported | [(0.86)](/filings/0001493152-26-023129.md) | [0.18](/filings/0001493152-26-039249.md) | [1.48](/filings/0001493152-25-022359.md) | not reported | [(1.43)](/filings/0001493152-26-023129.md) | [(0.70)](/filings/0001493152-26-039249.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: not reported - Interest expense: us-gaap:InterestExpense - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | period not labelled (2025-10-31) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [1.5](/filings/0001493152-25-010973.md) | [0.7](/filings/0001493152-24-019301.md) | [0.5](/filings/0001493152-24-033150.md) | [0.3](/filings/0001493152-24-045124.md) | [2.0](/filings/0001493152-26-012916.md) | [0.3](/filings/0001641172-25-010401.md) | [0.6](/filings/0001641172-25-023517.md) | [4.5](/filings/0001493152-25-022359.md) | [2.7](/filings/0001493152-26-012916.md) | [1.5](/filings/0001493152-26-039249.md) | [0.3](/filings/0001493152-26-023129.md) | [0.3](/filings/0001493152-26-039249.md) | | Current assets | $m | [27.0](/filings/0001493152-25-010973.md) | [39.4](/filings/0001493152-24-019301.md) | [33.7](/filings/0001493152-24-033150.md) | [26.4](/filings/0001493152-24-045124.md) | [38.1](/filings/0001493152-26-012916.md) | [20.7](/filings/0001641172-25-010401.md) | [40.5](/filings/0001641172-25-023517.md) | [298](/filings/0001493152-25-022359.md) | not reported | [214](/filings/0001493152-26-039249.md) | [128](/filings/0001493152-26-023129.md) | [88.7](/filings/0001493152-26-039249.md) | | Total assets | $m | [27.1](/filings/0001493152-25-010973.md) | [39.5](/filings/0001493152-24-019301.md) | [33.8](/filings/0001493152-24-033150.md) | [26.5](/filings/0001493152-24-045124.md) | [38.2](/filings/0001493152-26-012916.md) | [21.0](/filings/0001641172-25-010401.md) | [40.8](/filings/0001641172-25-023517.md) | [299](/filings/0001493152-25-022359.md) | not reported | [215](/filings/0001493152-26-039249.md) | [129](/filings/0001493152-26-023129.md) | [89.3](/filings/0001493152-26-039249.md) | | Current liabilities | $m | [1.0](/filings/0001493152-25-010973.md) | [0.2](/filings/0001493152-24-019301.md) | [0.7](/filings/0001493152-24-033150.md) | [1.3](/filings/0001493152-24-045124.md) | [4.2](/filings/0001493152-26-012916.md) | [0.5](/filings/0001641172-25-010401.md) | [4.9](/filings/0001641172-25-023517.md) | [62.4](/filings/0001493152-25-022359.md) | not reported | [63.4](/filings/0001493152-26-039249.md) | [44.3](/filings/0001493152-26-023129.md) | [43.1](/filings/0001493152-26-039249.md) | | Total liabilities | $m | not reported | not reported | not reported | not reported | [4.2](/filings/0001493152-26-012916.md) | not reported | [9.7](/filings/0001641172-25-023517.md) | [73.5](/filings/0001493152-25-022359.md) | not reported | [75.2](/filings/0001493152-26-039249.md) | [56.9](/filings/0001493152-26-023129.md) | [50.4](/filings/0001493152-26-039249.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [26.2](/filings/0001493152-26-012916.md) | [39.3](/filings/0001641172-25-023517.md) | [33.1](/filings/0001493152-25-022359.md) | [25.2](/filings/0001493152-25-022359.md) | [34.0](/filings/0001493152-26-039249.md) | [20.6](/filings/0001493152-26-039249.md) | [31.1](/filings/0001493152-26-039249.md) | [225](/filings/0001493152-25-022359.md) | not reported | [139](/filings/0001493152-26-039249.md) | [72.1](/filings/0001493152-26-039249.md) | [38.8](/filings/0001493152-26-039249.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Current portion of debt: not reported - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(648) d](/filings/0001493152-24-045124.md) | [(869) d](/filings/0001493152-25-010973.md) | [(769)](/filings/0001641172-25-010401.md) | [(924) d](/filings/0001641172-25-023517.md) | [(695) d](/filings/0001493152-25-022359.md) | [(1,142) d](/filings/0001493152-26-012916.md) | [(1,902)](/filings/0001493152-26-023129.md) | [(1,332) d](/filings/0001493152-26-039249.md) | [(2,798) d](/filings/0001493152-25-022359.md) | [(3,752) d](/filings/0001493152-26-012916.md) | [(1,242)](/filings/0001493152-26-039249.md) | [(22.2) d](/filings/0001493152-26-039249.md) | | Capital expenditure | $k | not reported | [0.0 d](/filings/0001493152-25-010973.md) | not reported | not reported | not reported | not reported | [1.7](/filings/0001493152-26-023129.md) | [1.8 d](/filings/0001493152-26-039249.md) | [4.6 d](/filings/0001493152-25-022359.md) | [4.7 d](/filings/0001493152-26-012916.md) | not reported | not reported | | Dividends paid | $k | [0.0 d](/filings/0001493152-23-040107.md) | [0.0 d](/filings/0001493152-24-010797.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1,000 d](/filings/0001493152-26-012916.md) | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [13.0](/filings/0001493152-23-040107.md) | [17.2](/filings/0001493152-24-019301.md) | [13.9](/filings/0001493152-24-033150.md) | [14.3](/filings/0001493152-24-045124.md) | [19.4](/filings/0001641172-25-010401.md) | [15.8](/filings/0001641172-25-023517.md) | [16.2](/filings/0001493152-25-022359.md) | [20.0](/filings/0001493152-26-023129.md) | [27.9](/filings/0001493152-26-039249.md) | [50.3](/filings/0001493152-25-022359.md) | [48.2](/filings/0001493152-26-023129.md) | [49.8](/filings/0001493152-26-039249.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 52,471,941 at 2026-08-17, from the cover of the [10-Q filed 2026-08-19](/filings/0001493152-26-039249.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.